Equity research analysts tracking OraSure Technologies (NASDAQ: OSUR) maintain a cautious outlook, reflecting near-term profitability pressures and variable revenue cycles following post-pandemic public health demand fluctuations. Financial forecasting models project a consensus hold rating, with average 12-month target prices hovering around the $3.00 range, while institutional watchers closely monitor its new product pipelines, diagnostic clearances, and cash burn metrics.